Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

Similar articles for PubMed (Select 23387914)

1.

Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.

Trost LW, Serefoglu E, Gokce A, Linder BJ, Sartor AO, Hellstrom WJ.

J Sex Med. 2013 Feb;10 Suppl 1:84-101. doi: 10.1111/jsm.12036. Review.

PMID:
23387914
2.

Androgen deprivation therapy: evidence-based management of side effects.

Ahmadi H, Daneshmand S.

BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25. Review.

PMID:
23351025
3.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

4.

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

Higano CS.

Urology. 2003 Feb;61(2 Suppl 1):32-8. Review.

PMID:
12667885
5.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

6.

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

Grossmann M, Zajac JD.

Clin Endocrinol (Oxf). 2011 Mar;74(3):289-93. doi: 10.1111/j.1365-2265.2010.03939.x.

PMID:
21092052
7.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.

Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Review.

PMID:
23628492
8.

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.

Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL; FinnProstate Group.

Eur Urol. 2013 Jan;63(1):111-20. doi: 10.1016/j.eururo.2012.07.040. Epub 2012 Jul 27.

PMID:
22857983
9.

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.

Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM; TAP22 Investigators Group.

BJU Int. 2012 Nov;110(9):1262-9. doi: 10.1111/j.1464-410X.2012.11120.x. Epub 2012 Apr 13.

PMID:
22502816
10.

Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review.

Gardner JR, Livingston PM, Fraser SF.

J Clin Oncol. 2014 Feb 1;32(4):335-46. doi: 10.1200/JCO.2013.49.5523. Epub 2013 Dec 16. Review.

PMID:
24344218
11.

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.

DiBlasio CJ, Malcolm JB, Derweesh IH, Womack JH, Kincade MC, Mancini JG, Ogles ML, Lamar KD, Patterson AL, Wake RW.

BJU Int. 2008 Jul;102(1):39-43. doi: 10.1111/j.1464-410X.2008.07505.x. Epub 2008 Feb 21.

PMID:
18294309
12.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
13.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
14.
15.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

16.

Androgen deprivation therapy complications.

Allan CA, Collins VR, Frydenberg M, McLachlan RI, Matthiesson KL.

Endocr Relat Cancer. 2014 Aug;21(4):T119-29. doi: 10.1530/ERC-13-0467. Epub 2014 May 28. Review.

17.

Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.

Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M.

J Sex Med. 2012 Mar;9(3):887-902. doi: 10.1111/j.1743-6109.2011.02590.x. Epub 2012 Jan 16. Review.

PMID:
22248394
18.

Androgen deprivation therapy for prostate cancer.

Sharifi N, Gulley JL, Dahut WL.

JAMA. 2005 Jul 13;294(2):238-44. Review.

PMID:
16014598
19.

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

Basaria S.

J Androl. 2008 Sep-Oct;29(5):534-9. doi: 10.2164/jandrol.108.005454. Epub 2008 Jun 20. Review.

20.

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.

J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. Epub 2007 Oct 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk